Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable
pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused
ultrasound (HIFU)/FOLFIRINOX combined treatment is performed on patients who agree to this
study. The combined treatment group is treated in parallel with FOLFIRINOX and HIFU for the
first four cycles and then CT is taken for reaction evaluation immediately, 2 months, and 4
months after the four-cycle treatment. For the response assessment, the response rate using
RECIST ver. 1.1 and operable rate are evaluated and compared with the results of already
established FOLFIRINOX single treatment in the investigators' institute. Time-to-progress and
overall survival are calculated.
Phase:
N/A
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Focused Ultrasound Foundation Synex Consulting Ltd